CD80 and focal segmental glomerulosclerosis: A study by Yu et al. showed that B7–1 (CD80) overexpression was induced in podocytes in primary and recurrent FSGS and reported the efficacy of abatacept in four post-transplantation patients (two adults and two children) with recurrent FSGS refractory to immunosuppression including rituximab, and one adult patient with FSGS in the native kidney [69].